Fluvoxin 50mg Tablet

Fluvoxamine is prescribed for specific psychiatric conditions rather than as a general-purpose antidepressant in every country.

• Obsessive-compulsive disorder (OCD): The U.S. immediate-release tablet is approved for obsessions and compulsions associated with OCD.

• Major depressive episodes: UK Faverin product information includes depression as an indication; availability and authorization can differ by country.

• Persistent obsessive thoughts and repetitive compulsive behaviors: Treatment aims to reduce the frequency and impact of these symptoms over time.

• Long-term symptom management: Continued treatment should be reviewed periodically by the prescriber rather than stopped suddenly.

Fluvoxamine is not intended to provide an immediate calming or mood-lifting effect. Antidepressant treatment may take time to produce noticeable improvement.

Fluvoxamine is an SSRI. It primarily works by reducing the reuptake of serotonin by nerve cells, increasing serotonin availability in the spaces between neurons. Changes in serotonin signaling are thought to contribute to improvement in obsessive-compulsive symptoms and depressive symptoms.

The therapeutic effect develops gradually rather than immediately. This is important when assessing treatment response: patients should not independently increase the dose because improvement is not noticed after a few days. Regular medical review helps determine whether the dose and treatment duration remain appropriate.

The 50mg strength is commonly used as a starting dose for adults with OCD, but the appropriate regimen depends on the diagnosis and the specific product information being followed.

Situation	Label-based example
Adult OCD	U.S. immediate-release labeling starts at 50mg once daily at bedtime
Dose adjustment	May be increased gradually by 50mg at intervals of 4–7 days as tolerated
Maximum adult dose	Up to 300mg/day under U.S. labeling
Higher daily doses	Doses above 100mg/day should generally be divided
Liver impairment	Lower starting dose and careful monitoring may be required

These are general prescribing references, not an individual dose recommendation. Dose selection depends on the condition, age, response, other medicines and liver function.

Take Fluvoxin exactly as prescribed and maintain a consistent dosing schedule. The regular tablet should be swallowed with water and should not be confused with the separately marketed CR formulation.

• Follow the prescribed timing and dose rather than adjusting treatment according to day-to-day symptoms.

• Fluvoxamine tablets may be taken with or without food according to product instructions.

• Do not stop treatment abruptly. Fluvoxamine should generally be reduced gradually under medical supervision to limit withdrawal symptoms.

• If a dose is missed, follow the instructions from the prescriber or pharmacist rather than doubling the next dose.

Common adverse effects can include nausea, headache, sleep disturbance, dizziness, sweating and sexual dysfunction. Side effects may change as treatment continues, but persistent or troublesome effects should be discussed with the prescriber.

Important interaction considerations include:

• MAO inhibitors: Contraindicated because of the risk of serious serotonin toxicity.

• Tizanidine: Contraindicated with fluvoxamine.

• Pimozide, thioridazine and alosetron: Contraindicated with immediate-release fluvoxamine under U.S. labeling.

• Other serotonergic medicines: Combining them can increase the risk of serotonin syndrome.

• Medicines metabolized by CYP enzymes: Fluvoxamine can significantly alter exposure to several medicines, so the complete medication list should be reviewed.

Fluvoxin requires medical supervision because fluvoxamine can cause clinically important psychiatric, neurological and drug-interaction effects. Antidepressants carry a warning regarding increased suicidal thoughts and behavior in children, adolescents and young adults, particularly when treatment is started or the dose is changed. Patients and caregivers should report significant worsening of mood, unusual behavioral changes or thoughts of self-harm promptly.

Do not combine fluvoxamine with contraindicated MAO inhibitors, tizanidine, pimozide, thioridazine or alosetron. Serotonin syndrome can occur with serotonergic medicines and may cause agitation, sweating, tremor, rapid heartbeat, fever, muscle rigidity or confusion. Fluvoxamine should also be used cautiously in people with liver disease, epilepsy, a history of mania/hypomania or significant bleeding risk.

Pregnancy and breastfeeding should be discussed with a healthcare professional. Do not stop Fluvoxin suddenly, as withdrawal symptoms can occur. Seek urgent medical help for severe allergic reactions, seizures, severe confusion or agitation, manic symptoms, significant bleeding, or thoughts of self-harm.

This information is for general education and does not replace advice from a doctor, pharmacist or qualified healthcare professional.